Sign Up
OverviewAPI
Incyte and Syndax present positive data from the AGAVE-201 clinical trial for axatilimab, an anti-CSF-1R antibody, in refractory chronic graft-versus-host disease (GVHD) patients. The study achieved its primary endpoint in all dosage cohorts, with 74% of patients achieving complete or partial response within the first six months of treatment. Both companies plan to submit a Biologics License Application (BLA) for axatilimab by the end of 2023.

Ask a question